{"status":"OK","data":{"advertisement":{"id":246848,"title":"REQUEST FOR QUOTATION no. 08 04 2024 MM - Purchase and delivery / granting of access to the license of scientific software for the prediction and identification of drug metabolites.","partial_offer_allowed":false,"publication_date":"2024-04-08","submission_deadline":"2024-04-15 23:59:59","planned_sign_date":"2024-05-01","supplementary_orders":null,"terms_of_contract_change":"VIII.3.\tThe Ordering Party provides for the possibility of amending the terms of the contract concluded as a result of this procedure:\na.\tin the event of a change in applicable legislation if it becomes necessary to adapt the content of the agreement to the current state of the law (including applicable standards),\nb.\tin the event that the necessity to introduce changes results from changes in the guidelines, recommendations or decisions issued by the Institution which granted the funds for financing the agreement,\nc.\tin the event of a change in the rate of goods tax on a product which is the subject of the agreement, \nd.\textension of the license period - the Ordering Party reserves the option to renew the license for additional years during the duration of the Project(s). Before the end of the current license period, the Ordering Party will request the Vendor to send a quote for the following year. The Ordering Party reserves the right to renew the license if the price for the following year is no more than 15% higher than the price for the current year.\ne.\tcontract duration - the Ordering Party reserves the right to amend the expected date of contract execution as a result of changes in the scope of the signed agreement for the co-financing of the Projects (extension of the duration of the Projects or their stages),\nf.\tnumber, configuration and license type - the Ordering Party reserves the right to change the number, configuration and type of licenses according to the needs of the Project(s),\ng.\toccurrence of force majeure - the Ordering Party reserves the right to amend the terms of the contract concluded as a result of this procedure also in the event of the occurrence of force majeure understood as an event that substantially impedes the performance of obligations under the grant contract, which the parties could not have foreseen and which they could not have prevented or overcome by acting with due diligence.\nh.\tin the case of conditions in accordance with section 3.2.4. para. 4.b -e. Guidelines on the eligibility of expenditure for the period 2021-2027 para. 4.b -e.","created_at":"2024-04-08 21:53:09","modified_at":"2024-04-16 00:00:04","contact_persons":[{"id":57,"forename":"Aleksandra","surname":"Mazga\u0142a","phone_number":"+48 538 899 945","email":"tenders@ryvu.com","created_by":null,"created_at":"2026-10-29 09:53:54","modified_at":"2026-10-29 09:53:54","modified_by":null}],"orders":[{"id":400409,"estimated_value":null,"order_items":[{"id":451465,"description":"In connection with the implementation of the projects entitled \u2018Development of targeted anticancer therapy based on inhibition of WRN helicase (CanSL)\u2019 applying for funding under call no. FENG.01.01-IP.02-002/23 (application number: FENG.01.01-IP.02-2086/23) as part of the European Funds for Smart Economy programme and \u2018Hi2Lo: AI drug design platform for small molecules oncology drugs\u2019 applying for funding under call no. FENG.01.01-IP.02-002/23 (application number: FENG.01.01-IP.02-2383/23) as part of the European Funds for Smart Economy programme and in connection with the obligation to make purchases on the basis of the most economically advantageous offer, observing the principles of fair competition, efficiency, openness and transparency, Ryvu Therapeutics S.A. submits a request for the purchase and delivery / granting of access to the license of scientific software for the prediction and identification of drug metabolites.\n\nPart of the contract: Part 1\nName and CPV code:  48461000-7 Analytical or scientific software package.\nPurchase and delivery / granting of access to the license of scientific software for the prediction and identification of drug metabolites.\n\nThe minimum set of functionalities:\nHigh-throughput metID software\nDedicated for broad acquisition mode (DDA, MSE, AIF, HDMSE, etc.)  \nImport of compound structures from various formats, at least: mol, SDF\nAllows selection of signal processing mode: MS, UV, Fluoroscence, Radio files\nElucidation of the structures of metabolites from accurate mass based on MS and MS/MS data\nAllows choosing metabolite generations and type of matrix brought into the analysis\nCompatible with most common file formats at least *.d, *.raw, *.RAW, *.wiff\nEnable assignment of chemical structure to each automatically detected chromatographic peak based on MS and MS/MS spectra\nBatch processing of datasets for a larger number of compounds\nAutomatically generated names of files for batch processed samples\nUser support after purchase (maintenance updates, email support)\n\nNumber of installations: two computers\nDuration: 1 year with the possibility of renewing the license for additional years during the duration of the Projects.\nDelivery: software download\n\nIn case of discrepancies between the provisions of the announcement on the Competitive Database and the provisions of the RFQ in the PDF version, the PDF version of the enquiry attached to the announcement shall be binding.\n","warranty_period":null,"cpv_items":[{"id":7258,"code":"48461000-7","name":"Analityczne lub naukowe pakiety oprogramowania"}],"timetable_items":[],"fulfillment_places":[{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":null,"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":null,"id":506392,"type":{"id":1,"name":"adres"},"group_uuid":"d6880fc9-9942-4263-b5ce-73e09742f703"}],"participation_conditions":[{"id":1238121,"description":"The evaluation of the conditions for participation in the procedure is carried out according to the meet-not meet system.\nDue to the prohibition of conflicts of interest, Contractors with personal or capital ties to the Ordering Party are excluded from the procedure. Equity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contractor selection procedure, and the Contractor, including in particular:\na.\tparticipation in a company as a partner in a civil law partnership or a partnership, holding at least 10% of shares (unless a lower threshold is specified by law), being a member of a supervisory or managerial body, a proxy, a proxy, \nb.\tthey are married, in a relationship of kinship or affinity in a straight line, or in a relationship of kinship or affinity in the collateral line to the second degree, or in a relationship of adoption, custody or guardianship, or in a shared life relationship with the economic operator, its legal deputy, or members of the management or supervisory bodies of contractors applying for the award of the contract, \nc.\tthey have such a legal or factual relationship with the economic operator that there is a reasonable doubt as to their impartiality or independence in connection with the contract award procedure.\nAssessment of the fulfillment of the above-mentioned condition will be made on the basis of a declaration of the Ordering Party.","type":{"id":7,"name":"Dodatkowe warunki udzia\u0142u"},"created_by":null,"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":null,"group_uuid":"63eb9f7a-a82a-474a-9fb0-2b4608146ec6"}],"category":{"id":3,"name":"Dostawa"},"subcategory":{"id":15,"name":"Dostawy inne"},"created_by":null,"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":null,"group_uuid":"30be0008-97df-4c6d-8bca-2fc152a33ba6"}],"evaluation_criteria":[{"id":688744,"price_criterion":true,"description":"Net price (\u2018C\u2019) - weight: 100% (10 points)","created_by":null,"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":null,"group_uuid":"05e8d29b-4f47-4cee-a01f-24612e5f786f"}],"is_variant":false,"title":"License","order_node":{"id":303565},"created_by":null,"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":null}],"created_by":{"id":112,"contact_persons":[]},"modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"advertiser_address_details":{"name":"RYVU THERAPEUTICS S.A.","identification_number_type":"nip","identification_number":"6792942955","address":{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":{"id":112,"contact_persons":[]},"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":{"id":112,"contact_persons":[]},"id":660447,"street":"Sternbacha","number_description":"2","postcode":"30-394"},"created_by":{"id":112,"contact_persons":[]},"created_at":"2024-04-08 21:53:09","modified_at":"2024-04-08 21:53:09","modified_by":{"id":112,"contact_persons":[]},"id":247407},"advertisement":{"id":187712,"number":"2024-112-187712","publication_date":"2024-04-08","created_by":{"id":112,"contact_persons":[]},"created_at":"2024-04-08 21:34:54","modified_at":"2024-04-16 00:00:04","modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":6,"label":"RESOLVED","name":"Rozstrzygni\u0119te"},"all_available_version_ids":[246844,246848],"enrollment":{"id":39917,"name":"Rozw\u00f3j celowanej terapii przeciwnowotworowej opartej o zahamowanie helikazy WRN (CanSL)","number":"002/23","activity":{"created_by":null,"created_at":"2023-02-01 09:22:25","modified_at":"2023-02-01 09:22:25","modified_by":null},"region":null,"institution":{"created_by":null,"created_at":"2023-02-01 09:28:01","modified_at":"2023-02-01 09:28:01","modified_by":null},"full_number":"FENG.01.01-IP.02-002/23","perspective":{},"programme":{"created_by":null,"created_at":"2023-02-01 09:21:41","modified_at":"2023-02-01 09:21:41","modified_by":null},"priority":{"created_by":null,"created_at":"2023-02-01 09:21:51","modified_at":"2023-02-01 09:21:51","modified_by":null},"type":"enrollment","created_by":null,"created_at":"2023-07-17 12:04:06","modified_at":"2023-07-17 12:04:06","modified_by":null},"projects":[],"is_author":false,"is_admin":false},"attachments":[{"origin":{"id":246848,"publication_date":"2024-04-08"},"id":1283581,"name":"Zapytanie ofertowe RFQ 08 04 2024 MM","file":{"id":1431035,"name":"RFQ 08 04 2024 MM.pdf","created_at":"2024-04-08 21:52:00","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/1431035"},"group_uuid":"01c1dc37-ff8d-4e59-829c-9c3b849c3afe"},{"origin":{"id":246848,"publication_date":"2024-04-08"},"id":1283582,"name":"Formularz ofertowy OFFER FORM 08 04 2024 MM","file":{"id":1431036,"name":"OFFER FORM 08 04 2024 MM.docx","created_at":"2024-04-08 21:52:14","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/1431036"},"group_uuid":"542875a2-248c-4b36-b490-e098cc761a33"}]},"dictionaries":{"announcement_status_draft":1,"announcement_status_published":2},"favorite":null,"badge":null,"offer_set_badge_count":null,"question_badge_count":null}}